Silence Therapeutics (SLN) Equity Ratio (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Equity Ratio for 7 consecutive years, with 0.47 as the latest value for Q4 2025.
- Quarterly Equity Ratio fell 28.33% to 0.47 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.47 through Dec 2025, down 28.33% year-over-year, with the annual reading at 0.47 for FY2025, 28.33% down from the prior year.
- Equity Ratio hit 0.47 in Q4 2025 for Silence Therapeutics, down from 0.5 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.66 in Q4 2024 to a low of 0.09 in Q4 2021.
- Historically, Equity Ratio has averaged 0.41 across 5 years, with a median of 0.49 in 2025.
- Biggest five-year swings in Equity Ratio: soared 263.95% in 2024 and later fell 28.33% in 2025.
- Year by year, Equity Ratio stood at 0.09 in 2021, then skyrocketed by 131.65% to 0.21 in 2022, then fell by 11.49% to 0.18 in 2023, then surged by 263.95% to 0.66 in 2024, then dropped by 28.33% to 0.47 in 2025.
- Business Quant data shows Equity Ratio for SLN at 0.47 in Q4 2025, 0.5 in Q3 2025, and 0.57 in Q2 2025.